New Haven, CT – [Insert Date] – Biohaven Pharmaceuticals has announced a significant pause in the pivotal clinical trials for its investigational epilepsy drug, opakalim (BHV-7000). The US Food and Drug Administration (FDA) has placed a partial clinical hold on the program, stemming from safety signals identified during the comprehensive characterization of a metabolite produced by opakalim in nonclinical rodent studies. This development casts a shadow over the drug’s path to market and introduces new uncertainty into the competitive landscape for focal epilepsy treatments.
n
The partial hold means that while Biohaven can continue to dose patients already enrolled in its two pivotal trials, RISE-2 (NCT06132893) and RISE-3 (NCT06309966), as well as an associated open-label extension study (NCT06443463), new patient recruitment has been halted. The company has communicated this situation to global regulatory bodies, acknowledging that there is "insufficient information" regarding the potential risks to humans posed by a specific opakalim metabolite. This metabolite was identified through extensive nonclinical testing, primarily in rodent models.
n
The pause is expected to have a more immediate impact on the RISE-2 trial, as the RISE-3 trial has already completed its enrollment and randomization phase. Biohaven anticipates that the timeline for RISE-3, with a projected readout in the latter half of 2026, will remain largely unaffected by this hold. However, the need for further nonclinical data generation on the metabolite’s safety in humans introduces a critical variable that could influence future regulatory decisions and the overall development timeline for opakalim.
n
This setback comes shortly after SK Biopharmaceuticals acquired the global rights to opakalim from Biohaven in a deal valued at $350 million upfront. Notably, SK Biopharmaceuticals was privy to all existing clinical and nonclinical data, including the metabolite characterization studies, prior to the finalization of the agreement. This raises questions about the extent to which this new safety information was factored into the acquisition’s valuation and the strategic considerations for SK Biopharmaceuticals moving forward.
n
Opakalim, developed as a selective opener of voltage-gated potassium channels Kv7.2 and 7.3, is designed to modulate neuronal excitability and thus combat seizures. These specific potassium channels play a crucial role in regulating the electrical activity of nerve cells in the central nervous system. Biohaven’s approach aims to restore a more balanced neural signaling, a mechanism that has shown promise in the treatment of focal onset seizures.
n
However, opakalim’s development journey has not been without its challenges. This current pause follows previous pivotal study failures in 2025 for indications in bipolar disorder and major depressive disorder (MDD), underscoring the inherent complexities and high attrition rates in central nervous system drug development.
n
A Look Back: The Path to the Current Hold
n
The current situation with opakalim’s pivotal trials represents a critical juncture in its development. To understand the implications, it’s essential to trace the recent events:
n
- n
- [Date of SK Biopharma Deal]: SK Biopharmaceuticals enters into a significant licensing agreement with Biohaven, acquiring global rights to opakalim (BHV-7000) for an upfront payment of $350 million. At this stage, all available nonclinical and clinical data, including the metabolite characterization, was disclosed to SK Biopharmaceuticals.
- [Recent Date, e.g., a few days before the news]: Biohaven communicates with global regulators, including the FDA, regarding safety signals identified in nonclinical studies. These signals pertain to a specific metabolite of opakalim.
- [Date of FDA Notification]: The FDA issues a partial clinical hold on Biohaven’s pivotal trials evaluating opakalim for focal epilepsy. This hold prohibits new patient enrollment.
- [Present Day]: Biohaven formally announces the partial clinical hold and its implications for the ongoing clinical program.
n
n
n
n
n
The company’s 8-K filing to the Securities and Exchange Commission (SEC) provided further details, confirming the "insufficient information" regarding the human risk profile of the identified metabolite. This necessitates further investigation and characterization before new patients can be enrolled in the pivotal trials.
n
The Impact on Ongoing Trials
n
The FDA’s partial clinical hold has a targeted but significant impact on Biohaven’s focal epilepsy development program. The trials affected are:
n
- n
- RISE-2 (NCT06132893): This pivotal trial is designed to evaluate the efficacy and safety of opakalim in patients with focal onset seizures. The halt in new enrollment will likely extend the recruitment period for this study.
- RISE-3 (NCT06309966): This second pivotal trial, also evaluating opakalim for focal epilepsy, has already completed its enrollment and randomization. Therefore, the partial hold is not expected to affect its progression or the timeline for data readout.
- Open-label extension study (NCT06443463): Existing patients from the pivotal trials can continue to receive opakalim in this extension study, ensuring continuity of care for those already benefiting from the investigational therapy.
n
n
n
n
Biohaven has emphasized that the company is fully cooperating with the FDA and other regulatory bodies to generate the required nonclinical data. The focus is on meticulously characterizing the opakalim metabolite, understanding its pharmacokinetic and pharmacodynamic properties, and definitively assessing its safety profile in humans. This data will be crucial for the FDA to determine the conditions under which the clinical hold can be lifted.
n
Understanding the Science Behind Opakalim
n
Opakalim’s mechanism of action targets the Kv7.2 and Kv7.3 potassium channels. These channels are integral to the control of neuronal excitability. By selectively opening these channels, opakalim aims to hyperpolarize neurons, making them less likely to fire action potentials. This dampening of excessive neuronal activity is the fundamental principle behind its potential as an anti-seizure medication.
n
The identification of a metabolite with potential safety concerns, even in nonclinical studies, highlights the complex metabolic pathways drugs undergo within the body. Sometimes, metabolites can be more active, less active, or even possess different toxicological profiles than the parent drug. Thorough characterization of these metabolites is a standard and critical part of drug development, especially for novel compounds.
n
The Competitive Landscape: A Race for Focal Epilepsy Market Share
n
The focal epilepsy market is a significant and growing area of pharmaceutical development. Biohaven is not alone in pursuing novel treatments for this condition. Xenon Pharmaceuticals is a key competitor with its own Kv7 opener, azetukalner, which is also in late-stage development for focal epilepsy.
n
Xenon has announced plans to submit a New Drug Application (NDA) to the FDA for azetukalner in the third quarter of 2026. If successful, azetukalner could become the first drug from this specific class to reach the market for focal epilepsy. This timeline places it ahead of opakalim, especially given the current developmental pause.
n
The market for anti-seizure medications is already well-established, with a range of existing therapies available. However, there remains a significant unmet need for patients who do not achieve adequate seizure control with current treatments or who experience debilitating side effects. Both opakalim and azetukalner aim to address these gaps by offering a novel mechanism of action.
According to market analysis from GlobalData, parent company of Clinical Trials Arena, the global market for adult epilepsy is projected to be worth $17.8 billion by 2035 across the seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan). This substantial market size underscores the commercial potential for innovative therapies that can demonstrate clear efficacy and safety benefits.
Official Responses and Future Outlook
Biohaven’s official statements have focused on transparency and a commitment to rigorous scientific investigation. The company has reiterated its belief in the potential of opakalim and its dedication to addressing the FDA’s concerns promptly and thoroughly.
"We are committed to working closely with the FDA to address their questions regarding the safety of an opakalim metabolite," stated a Biohaven spokesperson. "Patient safety is our utmost priority, and we will conduct the necessary nonclinical studies to fully characterize this metabolite and ensure the continued safe development of opakalim for patients with focal epilepsy."
The implications of this partial clinical hold are multifaceted. For Biohaven, it represents a significant hurdle and potential delay in bringing a promising asset to market. The financial implications of extended development timelines and the need for additional studies could also be considerable.
For SK Biopharmaceuticals, the acquisition of opakalim now carries a degree of heightened risk. While they were aware of the metabolite characterization data, the FDA’s subsequent action highlights a potential regulatory challenge that may not have been fully anticipated or its implications fully appreciated at the time of the deal. Their strategic planning for the drug’s future commercialization will need to account for this developing situation.
For patients and the wider epilepsy community, the pause is a source of understandable concern. While the existing patients can continue treatment, the delay in new patient enrollment could mean a longer wait for broader access to a potentially novel therapeutic option. The field of epilepsy treatment is constantly evolving, and the success of opakalim, or indeed azetukalner, could significantly impact treatment paradigms.
The coming months will be crucial for Biohaven as it works to generate the necessary data to satisfy the FDA’s requirements. The company’s ability to efficiently and effectively characterize the opakalim metabolite and demonstrate its safety in humans will be the determining factor in lifting the partial clinical hold and resuming the pivotal trials. The outcome will not only shape the future of opakalim but also have a ripple effect on the competitive dynamics of the focal epilepsy market.
